- Home
- RGT vs MGNX Comparison
RGT vs MGNX Comparison
Compare RGT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- MGNX
- Stock Information
- Founded
- RGT 1986
- MGNX 2000
- Country
- RGT United States
- MGNX United States
- Employees
- RGT N/A
- MGNX N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- RGT Finance
- MGNX Health Care
- Exchange
- RGT Nasdaq
- MGNX Nasdaq
- Market Cap
- RGT 83.4M
- MGNX 99.7M
- IPO Year
- RGT N/A
- MGNX 2013
- Fundamental
- Price
- RGT $12.86
- MGNX $1.69
- Analyst Decision
- RGT
- MGNX Hold
- Analyst Count
- RGT 0
- MGNX 6
- Target Price
- RGT N/A
- MGNX $3.20
- AVG Volume (30 Days)
- RGT 22.4K
- MGNX 548.7K
- Earning Date
- RGT 01-01-0001
- MGNX 11-04-2025
- Dividend Yield
- RGT 1.43%
- MGNX N/A
- EPS Growth
- RGT N/A
- MGNX N/A
- EPS
- RGT 0.92
- MGNX N/A
- Revenue
- RGT N/A
- MGNX $165,495,000.00
- Revenue This Year
- RGT N/A
- MGNX N/A
- Revenue Next Year
- RGT N/A
- MGNX N/A
- P/E Ratio
- RGT $11.42
- MGNX N/A
- Revenue Growth
- RGT N/A
- MGNX 303.47
- 52 Week Low
- RGT $7.84
- MGNX $0.99
- 52 Week High
- RGT $11.08
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- RGT 49.64
- MGNX 49.89
- Support Level
- RGT $12.47
- MGNX $1.56
- Resistance Level
- RGT $13.16
- MGNX $1.77
- Average True Range (ATR)
- RGT 0.24
- MGNX 0.10
- MACD
- RGT -0.02
- MGNX -0.01
- Stochastic Oscillator
- RGT 56.74
- MGNX 48.15
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.